Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TELO
STRONG SELLTelomir Pharmaceuticals, Inc. · Healthcare · United States · $79M · Avg Vol: $167K/d
11
StockRankGet insider-trade alerts
Q
26
V
24
M
37
P/E (TTM)
—
ROE
-384.3%
D/E
0.1x
Dividend %
—
Loading 1Y...
PRICE (1Y)-2.4%
SMA 50SMA 200
Close
$1.23
RSI (14)
49.4
52W High
$2.32
From 52W High
0.5%
SCORE BREAKDOWN
Quality
26
ROIC
-156.0%3.6
ROE
-384.3%2.0
GP/Assets
—N/A
Op. Margin
0.0%41.3
FCF/Assets
-20.4%18.2
Piotroski
239.0
Int. Cover
-50.0x6.3
D/E Ratio
0.11x61.7
Current Ratio
7.00x79.9
Value
24
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
8.0x14.7
P/S
—N/A
Div Yield
—N/A
Momentum
37
52W High %
53%29.8
RS 6M
-16%52.0
SMA 50/200
0.93x49.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+3%23.5
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$79M
P/E (Forward)
-4.1x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TELO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TELO | Telomir Pharmaceuticals, Inc.(you) | $79M | 11 | STRONG SELL |
| MAIA | MAIA Biotechnology, Inc. | $75M | 12 | STRONG SELL |
| BMEA | Biomea Fusion, Inc. | $90M | 10 | STRONG SELL |
| GANX | Gain Therapeutics, Inc. | $75M | 8 | STRONG SELL |
| HRTX | Heron Therapeutics, Inc. | $86M | 8 | STRONG SELL |
| IBIO | iBio, Inc. | $71M | 9 | STRONG SELL |
| CGTX | Cognition Therapeutics, Inc. | $82M | 7 | STRONG SELL |
| KLRS | Kalaris Therapeutics, Inc. | $89M | 9 | STRONG SELL |
| IMA | ImageneBio, Inc. | $63M | 11 | STRONG SELL |
| CING | Cingulate Inc. | $62M | 11 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%